Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCaledonia Regulatory News (CLDN)

Share Price Information for Caledonia (CLDN)

Share Price is delayed by 15 minutes
Get Live Data
352.00    -5.50 (-1.54%)
Bid:
351.00
Ask:
352.50
Spread: 1.50 (0.427%)
Market Cap: £1.80b
CLDN Live PriceLast checked at - London Stock Exchange

Intraday Caledonia Share Chart

Director/PDMR Shareholding

3 Jun 2025 16:05

RNS Number : 2749L
Caledonia Investments PLC
03 June 2025
 

Caledonia Investments plc

Notification of transactions of persons discharging managerial responsibilities ("PDMR") or persons closely associated with them ("PCA")

 

Pursuant to the requirements of the UK Market Abuse Regulation, Caledonia Investments plc ("Caledonia" or the "Company") announces that on 30 May 2025 the following nil-cost options over ordinary 5p shares in Caledonia were granted to executive directors under the Caledonia Investments 2020 Performance Share Scheme (the "PSS") and in respect of compulsory deferral of bonus under the Caledonia Investments 2020 Deferred Bonus Plan (the "DBP"). The Company's share price used to determine the number of PSS awards and DBP awards was 3650p.

 

Executive Director

No. of shares over which PSS nil-cost options granted

No. of shares over which DBP nil-cost options granted

J M B Cayzer-Colvin

17,038

274

M S D Masters

21,575

673

R W Memmott

18,588

599

 

Subject to the rules of the PSS, nil-cost options are exercisable between three and ten years after the date of grant. Performance is measured over three years for one-third of the PSS awards which are subject to a post-vesting holding period, on an after-tax basis, of two years. The remaining two-thirds of the awards are subject to performance over five years.

 

Subject to the rules of the DBP, deferred share awards vest after a three-year retention period.

 

The total number of shares held under option by the above-named executive directors of Caledonia under the Company's share schemes following these nil-cost option grants are as follows:

 

Executive Director

Total no. of shares held under option under performance share schemes

Total no. of shares held under option under the DBP

J M B Cayzer-Colvin

110,079

6,154

M S D Masters

98,814

7,522

R W Memmott

55,384

599

 

Further information required by the UK Market Abuse Regulation in relation to these transactions is set out in the appendix below.

 

Enquiries:

Richard Webster

Company Secretary

Tel: + 44 20 7802 8080

 

3 June 2025

APPENDIX

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

James Michael Beale Cayzer-Colvin

2

 

Reason for the notification

 

a)

 

Position/status

 

Executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Caledonia Investments plc

b)

 

LEI

 

2138002FX1MYCA5ZZH32

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary 5p shares

 

 

 

GB0001639920

b)

 

Nature of the transaction

 

 

Grant of nil-cost options over ordinary 5p shares under:

(1) the Caledonia Investments 2020 Performance Share Scheme ("PSS")

 

(2) the Caledonia Investments 2020 Deferred Bonus Plan ("DBP")

 

c)

 

Price(s) and volume(s)

 

 

 

Description

Price(s)

 

Volume(s)

Grant of PSS award

 

£0.00

 

17,038

Grant of DBP award

 

£0.00

274

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

17,312

 

Nil

e)

 

Date of the transaction

 

30 May 2025

f)

Place of the transaction

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Mathew Simon Dexter Masters

2

 

Reason for the notification

 

a)

 

Position/status

 

Director/Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Caledonia Investments plc

b)

 

LEI

 

2138002FX1MYCA5ZZH32

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary 5p shares

 

 

 

GB0001639920

b)

 

Nature of the transaction

 

 

Grant of nil-cost options over ordinary 5p shares under:

 

(1) the Caledonia Investments 2020 Performance Share Scheme ("PSS")

 

(2) the Caledonia Investments 2020 Deferred Bonus Plan ("DBP")

 

c)

 

Price(s) and volume(s)

 

 

 

 

Description

Price(s)

 

Volume(s)

Grant of PSS award

 

£0.00

 

21,575

Grant of DBP award

 

£0.00

673

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

22,248

 

Nil

e)

 

Date of the transaction

 

30 May 2025

f)

Place of the transaction

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert William Memmott

2

 

Reason for the notification

 

a)

 

Position/status

 

Executive Director/Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Caledonia Investments plc

b)

 

LEI

 

2138002FX1MYCA5ZZH32

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary 5p shares

 

 

 

GB0001639920

b)

 

Nature of the transaction

 

 

Grant of nil-cost options over ordinary 5p shares under:

 

(1) the Caledonia Investments 2020 Performance Share Scheme ("PSS")

 

(2) the Caledonia Investments 2020 Deferred Bonus Plan ("DBP")

 

c)

 

Price(s) and volume(s)

 

 

 

 

Description

Price(s)

 

Volume(s)

Grant of PSS award

 

£0.00

 

18,588

Grant of DBP award

 

£0.00

599

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

19,187

 

Nil

e)

 

Date of the transaction

 

30 May 2025

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBUGDLDGGDGUX
Date   Source Headline
7th Sep 20231:50 pmRNSDirector/PDMR Shareholding
5th Sep 20237:00 amRNSCaledonia signs agreement to sell 7IM
7th Aug 20237:00 amRNSNet Asset Value(s)
19th Jul 20235:53 pmRNSResult of AGM
7th Jul 202310:22 amRNSNet Asset Value and Portfolio Update
15th Jun 20234:01 pmRNSAnnual Financial Report
9th Jun 20235:27 pmRNSDirector/PDMR Shareholding
6th Jun 202310:44 amRNSNet Asset Value(s)
1st Jun 20233:23 pmRNSDirector/PDMR Shareholding
23rd May 20237:00 amRNSDirectorate Change
23rd May 20237:00 amRNSFinal Results
9th May 20232:16 pmRNSNet Asset Value(s)
20th Apr 20239:40 amRNSAcquisition
12th Apr 202310:42 amRNSResponse to press speculation
11th Apr 20237:00 amRNSUnaudited net asset value and portfolio update
28th Mar 20231:50 pmRNSDirectorate Change
22nd Mar 20235:04 pmRNSDirector/PDMR Shareholding
14th Mar 20235:35 pmRNSDirector/PDMR Shareholding
6th Mar 20232:18 pmRNSNet Asset Value(s)
6th Feb 202311:47 amRNSNet Asset Value(s)
9th Jan 20237:00 amRNSUnaudited net asset value and portfolio update
7th Dec 20229:22 amRNSNet Asset Value(s)
22nd Nov 20227:00 amRNSDirectorate Change
22nd Nov 20227:00 amRNSHalf-year Report
7th Nov 202210:49 amRNSNet Asset Value(s)
7th Oct 20227:00 amRNSUnaudited net asset value and portfolio update
30th Sep 20224:21 pmRNSDirector/PDMR Shareholding
23rd Sep 20222:51 pmRNSDirector/PDMR Shareholding
6th Sep 202210:17 amRNSNet Asset Value(s)
23rd Aug 20225:21 pmRNSDirector/PDMR Shareholding
15th Aug 20222:21 pmRNSDirector Declaration
4th Aug 202212:41 pmRNSNet Asset Value(s)
27th Jul 20224:47 pmRNSResult of AGM
19th Jul 20224:59 pmRNSDirector Declaration
7th Jul 20227:00 amRNSUnaudited net asset value and portfolio update
23rd Jun 20224:00 pmRNSAnnual Financial Report
20th Jun 202212:20 pmRNSDirector/PDMR Shareholding
20th Jun 202212:20 pmRNSDirector/PDMR Shareholding
16th Jun 20224:32 pmRNSDirector/PDMR Shareholding
14th Jun 20221:51 pmRNSDirector/PDMR Shareholding
8th Jun 20229:36 amRNSNet Asset Value(s)
6th Jun 20223:33 pmRNSDirector/PDMR Shareholding
31st May 20224:50 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSFinal Results
6th May 20229:02 amRNSNet Asset Value(s)
7th Apr 20227:00 amRNSUnaudited net asset value and portfolio update
4th Apr 202210:10 amRNSDirectorate Change
25th Mar 20224:47 pmRNSDirector/PDMR Shareholding
21st Mar 20223:56 pmRNSDirector/PDMR Shareholding
16th Mar 20222:05 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.